Evaluating the Effect of Mucinex® 1200 mg on Mucociliary and Cough Clearance From the Human Lung
Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to test the ability of Mucinex, an oral,
over-the-counter, FDA approved expectorant) to stimulate the clearance of inhaled particles
from the subject's lungs (called "mucociliary clearance"). The study will also monitor the
metabolism of the drug by the subject's body.
Phase:
Phase 1
Details
Lead Sponsor:
University of North Carolina, Chapel Hill
Collaborators:
Reckitt Benckiser Inc. Reckitt Benckiser LLC
Treatments:
Chlorpheniramine, phenylpropanolamine drug combination Guaifenesin Phenylpropanolamine